siRNA targeting survivin inhibits the growth and enhances the chemosensitivity of hepatocellular carcinoma cells

Oncology Reports

Volumn 29, Issue 3, 2013, Pages 1183-1188

  Liu, Wensong ^a   Zhu, Feng ^a   Jiang, Yong ^a   Sun, Donglin ^a   Yang, Bo ^a   Yan, Haijiao ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Chemosensitivity; Hepatocellular carcinoma; RNA interference; Survivin

Indexed keywords

CASPASE 3; CISPLATIN; MESSENGER RNA; PLASMID VECTOR; RECOMBINANT RNA; SMALL INTERFERING RNA; SURVIVIN; TRYPAN BLUE;

APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CARCINOMA CELL; CELL ASSAY; CELL CYCLE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN HEPG2; CELL STRAIN SMMC 7721; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; FLOW CYTOMETRY; G0 PHASE CELL CYCLE CHECKPOINT; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HEP G2 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84872824349     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2196     Document Type: Article

References (32)

1. Mann CD, Neal C P, Garcea G, Manson MM, Dennison AR and Berry DP: Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 43: 979-992, 2007. (Pubitemid 46483030)
2. Sakae M, Kubo S, Takemura S, Sakata C, Uenishi T, Kodai S, Shinkawa H, Urata Y, Ohata K, Kaneda K, Nishioka T, Nozawa A and Suehiro S: Effect of interferon therapy on first and second recurrence after resection of hepatitis c virus-related hepatocel-lular carcinoma. Hepatol Res 42: 564-573, 2012.
3. Fuks D, Dokmak S, Paradis V, Diouf M, Durand F and Belghiti J: Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology 55: 132-140, 2012.
4. Barbare JC, Bouche O, Bonnetain F, Raoul JL, Rougier P, Abergel A, Boige V, Denis B, Blanchi A, Pariente A, Milan C and Bedenne L: Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol 23: 4338-4346, 2005. (Pubitemid 46207007)
5. Cabrera R and Nelson DR: Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 31: 461-476, 2010.
6. Kawaoka T, Aikata H, Takaki S, Katamura Y, Hiramatsu A, Waki K, Takahashi S, Hieda M, Toyota N, Ito K and Chayama K: Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepa-tocellular carcinoma. Cardiovasc Intervent Radiol 32: 687-694, 2009.
7. Wheatley SP and McNeish IA: Survivin: a protein with dual roles in mitosis and apoptosis. Int Rev Cytol 247: 35-88, 2005. (Pubitemid 41774364)
8. Liu J, Du W and Fan D: Survivin, the promising target in hepato-cellular carcinoma gene therapy. Cancer Biol Ther 7: 555-556, 2008. (Pubitemid 351847031)
9. Baykara M, Akkus M, Yildiz R, Gonul II, Dursun A, Coskun U, Benekli M, Sevinc A, Dane F and Buyukberber S: Survivin expression and its potential clinical significance in gastrointestinal stromal sarcoma. Int Immunopharmacol 11: 2227-2231, 2011.
10. Rodel F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R and Rodel C: Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 65: 4881-4887, 2005. (Pubitemid 40740827)
11. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T and Suzuki A: Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 31: 1080-1085, 2000. (Pubitemid 30233232)
12. Liu WS, Yan HJ, Qin RY, Tian R, Wang M, Jiang JX, Shen M and Shi CJ: siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity. Dig Dis Sci 54: 89-96, 2009.
13. Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, Kawaguchi Y, Fujimoto K, Wada M, Miyatake S and Imamura M: Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery 138: 299-305, 2005. (Pubitemid 41253814)
14. Zhang R, Ma L, Zheng M, Ren J, Wang T, Meng Y, Zhao J, Jia L, Yao L, Han H, Li K and Yang A: Survivin knockdown by short hairpin RNA abrogates the growth of human hepatocel-lular carcinoma xenografts in nude mice. Cancer Gene Ther 17: 275-288, 2010.
15. Zhang Y, Chen ZD, Du CJ, Xu G and Luo W: siRNA targeting survivin inhibits growth and induces apoptosis in human renal clear cell carcinoma 786-O cells. Pathol Res Pract 205: 823-827, 2009.
16. Guo X, Wang W, Zhou F, Lu Z, Fang R, Jia F, Bu X, Li R, Zhang B, Wu M and Wei L: siRNA-mediated inhibition of hTERT enhances chemosensitivity of hepatocellular carcinoma. Cancer Biol Ther 7: 1555-1560, 2008.
17. Altieri DC: New wirings in the survivin networks. Oncogene 27: 6276-6284, 2008.
18. Mita AC, Mita MM, Nawrocki ST and Giles FJ: Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 14: 5000-5005, 2008.
19. Zhao W, Bao P, Qi H and You H: Resveratrol down-regulates survivin and induces apoptosis in human multidrug-resistant SPC-A-1/CDDP cells. Oncol Rep 23: 279-286, 2010.
20. Ryan BM, O'Donovan N and Duffy MJ: Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 35: 553-562, 2009.
21. Yuan QZ, Wang CT, Mao YQ, Zhang P, Shi HS, Li ZY, Pan L, Yu DD, Leng F, Chen X, Ying W, Xu JH, Li W, Wu F, Wen Y, Ma TT and Wei YQ: Enhanced tumor radiosensitivity by a survivin dominant-negative mutant. Oncol Rep 23: 97-103, 2010.
22. Dai D, Liang Y, Xie Z, Fu J, Zhang Y and Zhang Z: Survivin deficiency induces apoptosis and cell cycle arrest in HepG2 hepatocellular carcinoma cells. Oncol Rep 27: 621-627, 2012.
23. Yang Z, Wang L, Wang H, Shang X, Niu W, Li J and Wu Y: A novel mimovirus vaccine containing survivin epitope with adjuvant IL-15 induces long-lasting cellular immunity and high antitumor efficiency. Mol Immunol 45: 1674-1681, 2008. (Pubitemid 351227403)
24. Couzin J: Breakthrough of the year. Small RNAs make big splash. Science 298: 2296-2297, 2002.
25. Klenov MS and Gvozdev VA: Heterochromatin formation: role of short RNAs and DNA methylation. Biochemistry 70: 1187-1198, 2005. (Pubitemid 41802113)
26. Nakahara K and Carthew RW: Expanding roles for miRNAs and siRNAs in cell regulation. Curr Opin Cell Biol 16: 127-133, 2004. (Pubitemid 38757288)
27. Nassar A, Lawson D, Cotsonis G and Cohen C: Survivin and caspase-3 expression in breast cancer: correlation with prognostic parameters, proliferation, angiogenesis, and outcome. Appl Immunohistochem Mol Morphol 16: 113-120, 2008.
28. Chiou SK, Jones MK and Tarnawski AS: Survivin - an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit 9: PI25-PI29, 2003. (Pubitemid 36565381)
29. Fields AC, Cotsonis G, Sexton D, Santoianni R and Cohen C: Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. Mod Pathol 17: 1378-1385, 2004. (Pubitemid 39472993)
30. Zhu H, Chen XP, Zhang WG, Luo SF and Zhang BX: Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma. World J Gastroenterol 11: 3855-3859, 2005. (Pubitemid 41025237)
31. Chen T and Deng C: Inhibitory effect of siRNA targeting survivin in gastric cancer MGC-803 cells. Int Immunopharmacol 8: 1006-1011, 2008.
32. Xu JH, Wang AX, Huang HZ, Wang JG, Pan CB and Zhang B: Survivin siRNA induces caspase-3-dependent apoptosis and enhances cisplatin sensitivity in squamous cell carcinoma of the tongue. Oncol Res 18: 377-385, 2010.